Valuation: Evotec SE

Market Cap 872M 995M 804M 753M 1.41B 93.82B 1.44B 9.66B 3.74B 46.37B 3.73B 3.65B 161B P/E 2026 *
-6.9x
P/E 2027 * -25.1x
Enterprise Value 886M 1.01B 817M 765M 1.43B 95.36B 1.46B 9.82B 3.8B 47.13B 3.8B 3.71B 163B EV / Sales 2026 *
1.2x
EV / Sales 2027 * 1.15x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
1 day+1.41%
1 week+5.96%
Current month-7.08%
1 month-2.08%
3 months+12.14%
6 months-8.95%
Current year-9.98%
1 week 4.57
Extreme 4.568
4.97
1 month 4.52
Extreme 4.516
5.33
Current year 4
Extreme 3.995
6.73
1 year 4
Extreme 3.995
7.84
3 years 4
Extreme 3.995
24.44
5 years 4
Extreme 3.995
45.83
10 years 3.61
Extreme 3.608
45.83
Manager TitleAgeSince
Chief Executive Officer 55 30/06/2024
Director of Finance/CFO - 30/04/2026
Chief Operating Officer - 30/04/2026
Director TitleAgeSince
Director/Board Member 58 18/06/2019
Director/Board Member 64 31/05/2021
Director/Board Member 43 21/06/2022
Date Insider Type Main position Quantity % Market Cap.
06-14Sell

Chief Technology Officer

-119,900 0.0674%
05-19Fiscal year

Chief Technology Officer

12,462 0.0070%
05-03Buy

Chief Technology Officer

15,367 0.0086%
Change 5-day change 1-year change 3-year change Capi.($)
+1.41%+5.96%-31.82%-75.76% 979M
-0.48%+7.20%-5.08%+2.45% 46.36B
+2.19%+11.71%+385.81%+632.13% 37.88B
+2.53%+13.93%+20.85%-10.61% 31.12B
+1.65%+3.61%+9.98%+55.42% 30.61B
-4.16%-2.58%+8.74%+15.22% 24.69B
-0.32%+12.96% - - 16.25B
+1.37%+14.53%+71.80%+134.14% 14.85B
+1.00%+10.30%+13.31%+22.84% 13.58B
+3.63%+9.53%+104.07%+107.62% 12.95B
Average +0.88%+8.91%+64.18%+98.16% 22.93B
Weighted average by Cap. +0.72%+8.98%+85.02%+138.12%

Financials

2026 *2027 *
Net sales 738M 841M 680M 637M 1.19B 79.36B 1.22B 8.17B 3.16B 39.22B 3.16B 3.09B 136B 818M 933M 754M 706M 1.32B 87.99B 1.35B 9.06B 3.51B 43.49B 3.5B 3.43B 151B
Net income -113M -129M -104M -97.71M -183M -12.18B -187M -1.25B -485M -6.02B -485M -474M -20.88B -30.42M -34.7M -28.04M -26.25M -49.23M -3.27B -50.25M -337M -130M -1.62B -130M -127M -5.61B
Net Debt 14.3M 16.31M 13.18M 12.34M 23.14M 1.54B 23.62M 158M 61.3M 760M 61.24M 59.9M 2.64B 69.32M 79.07M 63.9M 59.83M 112M 7.46B 115M 768M 297M 3.69B 297M 290M 12.78B
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,526
Date Price Change Volume
26/06/26 €4.906 +1.41% 459,786
25/06/26 €4.838 +0.58% 705,454
24/06/26 €4.810 +2.30% 1,002,560
23/06/26 €4.702 +0.69% 329,621
22/06/26 €4.670 +0.86% 330,860
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
4.906EUR
Average target price
6.443EUR
Spread / Average Target
+31.33%

Quarterly revenue - Rate of surprise